Developing a new method to create powerful biologic drugs
Chemical platform to produce covalent biologics
['FUNDING_R21'] · UNIVERSITY OF HOUSTON · NIH-10688088
This study is working on a new kind of medicine that could be stronger and need to be taken less often than current treatments, especially for conditions like cancer and inflammation, and it's for anyone looking for better options in their therapy.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10688088 on ClinicalTrials.gov |
What this research studies
This research aims to create a chemical platform that can produce covalent biologics, which are a new type of therapeutic drug. These drugs are designed to be more potent and require less frequent administration compared to traditional biologics. The researchers will use innovative techniques to enhance the yield of these drugs and enable rapid testing of multiple candidates. The project will focus on immune checkpoint inhibitors and anti-inflammatory therapeutics, utilizing both cell-based studies and animal models to validate the approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require treatment with biologic drugs, particularly those with conditions that could benefit from immune checkpoint inhibitors or anti-inflammatory therapies.
Not a fit: Patients who do not require biologic therapies or those with conditions not addressed by immune checkpoint inhibitors or anti-inflammatory treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less frequently administered biologic therapies for patients.
How similar studies have performed: While the approach of developing covalent biologics is innovative, similar research has shown promise in enhancing the efficacy of biologic drugs, indicating potential for success.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STATSYUK, ALEXANDER V — UNIVERSITY OF HOUSTON
- Study coordinator: STATSYUK, ALEXANDER V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.